Table 1.
Characteristics of Trials Included in the Meta-Analysis
| Study | Year | Design | Patients | Delivery Methods | Type | Dosing | Duration | Deaths: Control; Treated |
|---|---|---|---|---|---|---|---|---|
| Weg et al8 | 1994 | Multicenter: USA, Canada | 34 (C = 17, E = 17) | Aerosol | No protein | DPPC 43.5 mg/kg/d | 120 h | 8; 6 |
| Anzueto et al9 | 1996 | Multicenter: USA, Spain, France | 725 (C = 361, E = 364) | Aerosol | No protein | DPPC 112 mg/kg/d | 120 h | 143; 145 |
| Gregory et al10 | 1997 | Multicenter: USA | 32 (C = 16, E = 16) | Intratracheal | Proteins B + C | 100 mg/kg LBW | 96 h | 7; 3 |
| Spragg et al11 | 2003 | Multicenter: USA, Canada | 28 (C = 13, E = 15) | Intratracheal | Protein C | 1 mg/kg LBW, 4 doses | 24 h | 5; 3 |
| Spragg et al12 | 2004 | Multicenter: USA, Canada, Europe, South Africa | 448 (C = 224, E = 224) | Intratracheal | Protein C | 1 mg/kg LBW, 4 doses | 24 h | 72; 80 |
| I. Tsangaris et al14 | 2007 | University Hospital of Ioannina | 16 (C = 8, E = 8) | Intratracheal | Proteins B + C | Each segmental mg/kg (200/19) | single | 1; 0 |
| Markart et al13 | 2007 | University of Giessen Lung Center | 31 (C = 17, E = 14) | Intratracheal | Protein C | 1 mg/kg, 4 doses (PL 50 mg) | 24 h | 4; 4 |
| Jozef Kesecioglu et al15 | 2009 | Multicenter: North America, Europe, Austria | 418 (C = 210, E = 208) | Intratracheal | Proteins B + C | HL10 large boluses: 3 doses, total 600 mg/kg | 0 h, 12 h, 36 h | 51; 60 |
| Spragg et al16 | 2010 | Multicenter: North America, Europe | 843 (C = 424, E = 419) | Intratracheal | Protein C | rSP-C surfactant, 8 doses | >96 h | 101; 95 |
Abbreviations: C, control group; DPPC, dipalmitoyl phosphatidylcholine; E, experimental group; HL10, exogenous natural porcine surfactant HL 10 as large boluses; LBW, lead body weight; PL, phospholipids; rSP-C, recombinant surfactant protein C–based surfactant.